Investment in Mpox Detection Test by GHIT Fund
The Global Health Innovative Technology (GHIT) Fund has announced an investment of roughly JPY 70 million, translating to approximately USD 460,000, to develop a prototype detection test for mpox. This innovative step is vital in addressing the urgent healthcare needs concerning the spread of mpox, a viral disease that has seen a concerning rise across various regions.
Understanding Mpox
Mpox, formerly known as monkeypox, has been gaining attention due to its alarming prevalence, particularly noted in the Democratic Republic of the Congo (DRC) and other parts of sub-Saharan Africa. Reports indicate that, from early 2022 until late 2025, there were over 170,000 confirmed cases in over 140 countries. Surveillance data highlights a troubling statistic, where a significant portion of fatalities—approximately 62%—occurred in children under five years old, revealing a case fatality ratio between 7 to 9%. In light of this scenario, a Public Health Emergency of International Concern was declared in August 2024, due to the rapid spread of mpox in Africa.
Urgent Need for Diagnostic Tests
Mpox exhibits significant diversity, manifested through two distinct strains/clades, with varying infection rates and severity of illness. Currently, the existing diagnostic systems are not adequate to distinguish between these clades, which underscores the pressing need for rapid, straightforward diagnostic tests capable of identifying them effectively. The urgency in this area cannot be overstated when considering the public health implications of the ongoing mpox outbreak.
Collaboration for Innovation
The GHIT Fund's investment aims to bridge this gap by developing a prototype mpox detection test through a collaborative effort. Working alongside NIPRO CORPORATION, known for its advancements in healthcare, TBA Co., Ltd, a venture from Tohoku University, and the Japan Institute for Health Security, are key partners. Furthermore, the international non-profit PATH and the Institut National de Recherche Biomédicale (INRB) from the DRC are also integral to the project. The goal is to create an effective detection method, leveraging the Iso-PAS technique, which is recognized for its simplicity and cost-effectiveness, thus enabling testing even in resource-limited facilities.
Future Directions with GloPID-R
Recently, the GHIT Fund has joined the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), which is a significant step toward enhancing international collaboration in the funding of research for emerging infectious diseases. With this membership, the GHIT Fund is poised to bolster its commitment to developing innovative diagnostic technologies that can respond swiftly to future health crises.
About GHIT Fund
The GHIT Fund is a pioneering public-private partnership in Japan that comprises the Government of Japan, various pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). Its mission is to tackle neglected diseases that heavily affect vulnerable populations globally, facilitating the research and development of new treatments, vaccines, and diagnostic tools for pressing health challenges. This investment in mpox detection reflects a broader strategy to ensure global health security by mobilizing extensive partnerships across industries and sectors.
Frequently Asked Questions
What is the purpose of the GHIT Fund's investment?
The investment aims to develop a prototype detection test for mpox, enhancing diagnostic capabilities in resource-limited settings.
What strains of mpox are being targeted?
The project focuses on distinguishing between the two known mpox clades, which have varying impacts on disease severity.
What collaborative organizations are involved in this project?
The project includes NIPRO CORPORATION, TBA Co., Ltd, Japan Institute for Health Security, PATH, and INRB.
What testing method will be used in the mpox detection test?
The detection test will utilize the Iso-PAS method, an economical and straightforward genetic testing technique.
How does this investment align with global health goals?
This investment supports global health initiatives by enhancing preparedness for infectious diseases and improving diagnostic infrastructures worldwide.
